10 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 22026-10-06NCT03191149
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lymphatic Metastasis, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, metastatic malignant neoplasm in the lymph nodes, neoplasm, renal cell carcinoma, rhabdoid tumor of the kidney, sarcomatoid renal cell carcinoma, urinary system disorderActive, not recruitingPhase 32026-10-01NCT03793166
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerNeoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22026-09-29NCT04310007
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trialinvasive breast carcinomaActive, not recruitingPhase 22026-09-14NCT05710328
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapyinvasive breast carcinomaActive, not recruitingPhase 22026-09-14NCT04266249
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 32026-08-27NCT03811002
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 32026-07-01NCT03488693
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN StudyAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Hormone Receptor-Positive Breast CarcinomaActive, not recruitingNot applicable2026-04-02NCT05568472
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorderActive, not recruitingPhase 32026-02-10NCT01674140
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast CarcinomaRecruitingPhase 32025-11-05NCT05929768